Allurion Technologies announced it would begin a study to see if its gastric balloon, combined with popular GLP-1 medicines like Novo Nordisk's Wegovy, could improve muscle mass and overall body ...

James Manning / PA Images via Getty Images Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves ...

Allurion 创始人兼首席执行官Shantanu Gaur在一份声明中说：“我们研究的目标是证明，通过将Allurion Balloon和Allurion Virtual Care Suite与GLP-1治疗相结合，患者可以在增加肌肉质量和改善整体身体成分的同时显著减轻体重。” 诺和诺德(NVO.US)的semaglutide和礼来(LLY.US)的 ...

Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, ...

Allurion cited prior studies demonstrating that its gastric balloon, combined with its Virtual Care Suite, has helped patients lose weight while maintaining or even increasing muscle mass.

Allurion (NYSE: ALUR) surged 83% premarket after revealing a clinical study combining its gastric balloon product with GLP-1 drugs, showing muscle mass maintenance. Stardust Power (NASDAQ ...

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM gastric balloon for weight loss, the Allurion ...

Allurion is targeting the loss in lean mass seen in patients taking GLP-1RAs. Although its programme, which consists of an intragastric balloon and virtual care platform, does not lead to as much ...

Allurion added previous studies of patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite demonstrated outcomes in which patients lose weight while ...

Shares of Allurion (NYSE:ALUR) soared 70% in post-market trading Thursday after ending the regular session 21% higher on news the company plans to conduct a clinical study of its gastric balloon ...